TaiMed Biologics (4147.TWO) Earnings Analysis

TaiMed Biologics (4147.TWO) next reports earnings on 2026-08-07, consensus EPS -0.23 TWD. Last quarter (2026-03-03) it beat with EPS -0.25 TWD vs -0.28 TWD est (+10.7%). It has beaten estimates in 3/4 recent quarters (75%). Trailing P/E -128.26.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 4147.TWO next report earnings?

Next earnings date2026-08-07
Consensus EPS estimate-0.23 TWD
Revenue estimate0.16B

4147.TWO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-03-0.25 TWD-0.28 TWD+10.7%Beat
2025-08-07-0.22 TWD-0.24333 TWD+9.6%Beat
2025-03-05-0.44 TWD-0.17 TWD-158.8%Miss
2024-11-08-0.14 TWD-0.17 TWD+17.6%Beat

Beat rate: 3/4 (75%) over reported quarters with consensus data.

4147.TWO valuation and analyst view

Trailing P/E-128.26
Trailing EPS-0.46094 TWD
Price / book4.23
Dividend yield0.00%
Market cap15.81B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is TaiMed Biologics (4147.TWO)'s next earnings date?

TaiMed Biologics is next scheduled to report on 2026-08-07, with a consensus EPS estimate of -0.23 TWD and revenue estimate of 0.16B.

Did 4147.TWO beat earnings last quarter?

In its 2026-03-03 report, 4147.TWO posted EPS of -0.25 TWD versus a -0.28 TWD estimate — a beat of 10.7%.

What is 4147.TWO's earnings track record?

Over the last 4 reported quarters with consensus data, 4147.TWO beat estimates 3 times (75%).

What is 4147.TWO's current P/E ratio and EPS?

4147.TWO trades at a trailing P/E of -128.26 on trailing EPS of -0.4609423445968011 TWD.

What do analysts rate 4147.TWO?

4147.TWO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.